Business Wire

EARNIX

11.1.2023 18:37:39 CET | Business Wire | Press release

Share
Earnix Welcomes New CEO to Lead Next Stage of Global Expansion

Earnix, the market-leading provider of mission-critical cloud-based intelligent real-time, dynamic pricing and rating solutions for insurers and banks, today announced it is appointing insurance and fintech industry veteran, Robin Gilthorpe, as its new Chief Executive Officer effective February 1, 2023. Mr. Gilthorpe will be taking over the helm from Mr. Udi Ziv, who served as the company’s CEO over the past six years.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230111005784/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Robin Gilthorpe, CEO, Earnix (Photo: Business Wire)

Robin Gilthorpe, a veteran of the finance and insurance industries, brings to the role over 25 years of experience as a successful business leader. Throughout his career, Mr. Gilthorpe has held numerous executive leadership roles at leading technology and insurance companies such as TIBCO, Vertexone, Watersmart Software, DataSynapse and ESW Capital. In his most recent role at Insurtech innovator Salty, Gilthorpe served as Chief Operating Officer, generating a nine-figure outcome in sale to CDK Global.

“I am thrilled to be joining Earnix at this crucial time in the global economy,” said Robin Gilthrope, incoming CEO at Earnix. “Financial services companies across the globe are seeking intelligent operations to ensure they can offer real-time, dynamic solutions, to better serve customers, enabling them to be more agile, nimble, attentive, and responsive. Today’s end-customer demands unparalleled experience, alongside highly personalized and customizable solutions. Earnix solutions serve as the go-to platform for financial services companies to address the growing demands of the world’s leading financial and insurance companies.”

His hiring comes on the heels of a period of growth for Earnix led by exiting CEO Udi Ziv. Mr. Ziv joined Earnix in 2017 and in his six years with the firm has led the company to consistent growth, achieving Unicorn status and important strategic alliances including forging the recently announced strategic partnership with Guidewire as well as engagements with USAA, MAPFRE, IAG, Liberty Mutual, US Bank, Lloyd’s Banking Group, and many more. Mr. Ziv built a strong team of leaders positioned to drive the company’s continued growth. Udi will serve as one of the industry experts on the Earnix Board of directors.

“We are proud to welcome Robin to the Earnix family, and believe that his experience in building global, international companies, alongside the growing demand for Earnix’s suite of real-time, dynamic, composable Intelligent InsurOps solutions, will lead Earnix to significant growth over the next few years, and bring Earnix to international market leadership, with its real-time operation platform for the largest insurance companies and banking institutions,” said Erel Margalit, JVP Founder & Executive Chairman and Earnix's Chairman of the Board, “We want to thank Udi for his important role, over the last few years. With its growing presence in North America, Europe, Asia Pacific, and Israel, Earnix will continue to strive to become the category leader, in the real-time AI usage-based insurance and banking industry.”

“I’ve very much enjoyed my tenure at Earnix, leading the company to consistent year over year growth, and strongly believe in our people and products as a change agent for financial services companies,” Udi Ziv, exiting CEO, Earnix, said. “I believe now is the time to move on to my next endeavor as the company prepares for its next stage of international expansion. I firmly believe I am leaving the company in very capable hands with Robin and expect that the company will continue the rapid global growth Earnix has experienced in the last few years.”

About Earnix

Earnix is the premier provider of mission-critical composable and cloud-based intelligent solutions across pricing, rating, underwriting, product personalization and telematics. These fully integrated solutions provide ultra-fast ROI and are designed to transform how global insurers and banks are run by unlocking value across all facets of the business. It has been innovating for Insurers and Banks since 2001 with customers in over 35 countries across six continents and offices in the Americas, Europe, Asia Pacific, and Israel. Earnix shareholders include JVP, Insight Partners, IGP, and Vintage Investment Partners.

For more information please visit: earnix.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230111005784/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye